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AbstrACt
Introduction Age-related loss of muscle mass, muscle 
strength and muscle function (sarcopenia) leads to a 
decline in physical performance, loss of independence and 
reduced quality of life. Nutritional supplements may delay 
the progression of sarcopenia. The aim of this randomised, 
double-blinded controlled trial including 100 participants 
(≥65 years) is to assess the effect of a marine protein 
hydrolysate (MPH) on sarcopenia-related outcomes like 
hand grip strength, physical performance or gait speed and 
to study the associations between physical performance 
and nutritional intake and status.
Method and analysis The intervention group (n=50) 
will receive 3 g of MPH per day in 12 months. The control 
group (n=50) receive placebo. Assessments of Short 
Physical Performance Battery (SPPB), hand grip strength, 
anthropometric measurements, nutritional status as 
measured by the Mini Nutritional Assessment, dietary 
intake, supplement use, biomarkers of protein nutrition 
and vitamin D, and health-related quality of life (EQ-5D), 
will be performed at baseline and after 6 and 12 months 
of intervention. Linear mixed models will be estimated to 
assess the effect of MPH on SPPB, hand grip strength and 
quality of life, as well as associations between physical 
performance and nutrition.
Ethics and dissemination The study has been approved 
by the Regional Committee in Ethics in Medical Research 
in Mid-Norway in September 2016 with the registration 
ID 2016/1152. The results will be actively disseminated 
through peer-reviewed journals, conference presentations, 
social media, broadcast media and print media.
trial registration number NCT02890290.
IntroduCtIon 
Age-related loss of muscle mass, muscle 
strength and muscle function (ie, sarcopenia) 
leads to a decline in physical performance, 
loss of independence and reduced quality of 
life. The elderly are vulnerable for low phys-
ical activity and periods of bed rest, and they 
experience more severe loss of lean tissue/
muscle mass than younger adults do. Their 
muscles have a reduced ability to synthe-
sise muscle protein which leads to muscle 
wasting. This might be related to an anabolic 
signalling deficit and amino acid resistance in 
this population, as muscle protein synthesis 
(MPS) in response to the intake of amino 
acids is reduced in older people compared 
with younger populations.1 
Sarcopenia (muscular atrophy) is a chronic 
condition characterised by age-related loss of 
muscle mass, muscle strength and/or muscle 
function2; it can initiate disability and is 
related to the concept of frailty.3 Moreover, 
there is a correlation between sarcopenia and 
increased mortality.2 The prevalence of sarco-
penia is substantial in most geriatric settings 
and ranges from 1% to 29% in communi-
ty-dwelling populations and 14% to 33% in 
long-term care populations.4 Furthermore, 
it may be underdiagnosed and have multiple 
causes5 6 and is also associated with insulin 
resistance and low-grade inflammation.7
Exercise, diet and nutritional interven-
tions seem to have a preventive effect on the 
strengths and limitations of this study
 ► The study is designed as a randomised controlled 
trial, and the intervention is placebo controlled and 
double blinded.
 ► A strength of this study is the comprehensive data 
collection, with physical and anthropometric mea-
sures related to a thorough assessment of nutrition-
al intake, nutritional status and view on nutrition.
 ► The intervention period for this study is 6–12 
months, making the study appropriate for docu-
menting potential preventive effects on age-related 
loss of muscle function or strength.
 ► A limitation of this study may be the anthropometric 
method used to assess muscle mass.
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progression of sarcopenia.8 9 However, nutritional inter-
ventions are sparse and equivocal due to the low number 
of studies and their heterogeneous design.4 A recent 
meta-analysis concluded that the evidence for exercise 
and nutritional interventions in treating sarcopenia in 
older people is of low quality.10
Proteins and amino acids are among the nutrients 
suggested to counteract or delay sarcopenia,11 12 and a 
case–control study of sarcopenic and non-sarcopenic 
older people in the UK found lower protein intake (6%) 
among sarcopenic participants.13 A higher protein intake 
is recommended for older people, at least 1.0–1.2 g per 
kg of body weight daily to maintain muscle strength and 
function.11 There is also growing evidence that the distri-
bution of protein during the day might be as important 
as total intake, and that there might be a protein 
threshold regarding how much protein should be eaten 
at each meal to stimulate MPS.12 14 A dose–response study 
suggested that 20 g of whey protein was the optimal dose 
for young people, while a dose of 40 g had a more benefi-
cial effect for the elderly.15 However, elderly persons often 
have poor appetites, reduced uptake of nutrients from 
food and difficulties exercising. Thus, specific nutrient 
supplementation might benefit this population as part of 
a multimodal approach.16
Novel findings from the Maastricht Sarcopenia Study, 
presented at the 2016 Sarcopenia Cachexia and Wasting 
Disease conference in Berlin, showed that reduced levels 
of branched-chain amino acids in the blood seem to be 
associated with sarcopenia in older people.17 Hence, they 
need a greater amount of leucine and other essential 
amino acids to stimulate MPS compared with younger 
people. Leucine supplements partially protected muscle 
mass and function during bed rest in middle-aged men,18 
a protective effect that was not found in a study of young 
men.19
Marine proteins are leucine rich and well balanced 
in other essential amino acids. Furthermore, proteins 
from seafood may have properties different from those 
in meat. In a Norwegian intervention study using a cross-
over design, healthy volunteers consumed meals with 
similar compositions except for the protein source.20 The 
researchers found a decrease in risk factors for cardio-
vascular disease in the study group for which the protein 
source was fish. The diets were equal in terms of the distri-
bution of carbohydrates, proteins and fat, and cod liver oil 
was added to the meat meals to balance the long-chained 
fatty acids in fish. This provides evidence that fish protein 
may have a health effect per se. Supplementation with 
3 g fish protein (tablets) for 4 weeks had effects on body 
composition in overweight adults, including an increased 
percentage of body muscle and decreased percentage of 
body fat21
Protein hydrolysis, the cleavage of peptide bonds, 
results in smaller peptides that are easily digested and 
have greater resistance to gastric acid and heat.22 Hydro-
lysates of whey protein have been shown to stimulate 
MPS better than whole-protein soy and casein do, and 
this may be related to differences in absorption or small 
differences in leucine content.23 Hydrolysates of marine 
proteins have bioactive functions, and positive health 
effects have been noted in several areas.22 Nobile et al 
demonstrated that marine protein hydrolysate (MPH) 
had a positive effect on body composition in overweight 
adults in doses of 1.4 or 2.8 g.24
To our knowledge, no previous trials have tested MPH 
in community-dwelling elderly persons without additional 
training interventions.
The overall objective of this project is to study how 
nutritional status and dietary intake influence physical 
function in home-dwelling elderly persons.
This study aims to address the following hypotheses/
research questions:
1. Daily intake of 3 g MPH for 6–12 months prevents loss 
of physical performance as measured by the Short 
Physical Performance Battery (SPPB) compared with 
placebo.
2. Daily intake of 3 g MPH for 6–12 months prevents loss 
of muscle strength as measured by hand grip strength 
compared with placebo.
3. What are the associations between nutritional sta-
tus, intake of protein and physical performance and 
hand grip strength in older people?
dEsIgn And MEthods
study design
The study is a randomised controlled double-blinded 
trial. Comprehensive data collection will be used to 
examine the participants’ nutritional status and physical 
function. Data will be collected at baseline and 6 and 12 
months after the start of the intervention. Possible effects 
of the supplemented MPH will be assessed by examining 
differences between the intervention and placebo groups 
throughout the follow-up period.
recruitment
The participants will be men and women 65 years old 
and older. Exclusion criteria include active cancer illness 
or progressive muscle illness (eg, multiple sclerosis or 
Lou Gehrig’s disease), diabetes, kidney failure, short life 
expectancy (<1 year) and allergies to fish protein.
Participants will be recruited both through home care 
services and by advertising for volunteers. Health profes-
sionals in the municipal home care service will receive 
oral and written information about the intervention from 
the researcher and will be instructed to provide eligible 
participants with written information and an invitation 
to participate in the study. Recruiters will be further 
instructed to consider the elderly person’s capacity to 
give informed consent to participate before extending 
an invitation. Besides, recruiters will keep a register and 
report the number of elderly persons who do not meet 
the inclusion criteria, and the age and gender of those 
not willing to participate. Moreover, posters and flyers 
will be distributed at senior centres and elsewhere, for 
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volunteers to contact the researcher directly. Those who 
express their willingness to participate will receive a call 
from the researcher with additional information and the 
opportunity to ask questions before they decide whether 
to participate. If they decide to participate, a home visit 
is scheduled.
Recruitment will begin in one municipality and expand 
from there until 100 participants are included. All partic-
ipants will be asked to sign a letter of consent at the first 
home visit. Participants will be recruited and allocated 
from October 2017 to August 2018, and the follow-up 
time will be 1 year.
We do not anticipate this project causing any harm 
or discomfort to the participants, and we will ensure 
that our participants participate in the study voluntarily. 
Participants will be given both oral and written infor-
mation about the study twice before they provide their 
consent to participate. First, they will receive information 
from either posters/flyers or their home care nurse, and 
second, they will be offered the opportunity to ask the 
researcher questions directly before signing the written 
consent form. Furthermore, they will be informed about 
their right to withdraw from the study with no conse-
quences at any time.
Patient and public involvement
The baseline assessment was administered to elderly 
persons during the development of the study design; 
however, the burden of the intervention was not assessed 
by elderly people. Results from the study will be dissemi-
nated to study participants through newsletters and open 
lectures.
Assessments
The data collection will be completed in participants’ 
homes at baseline and after 6 and 12 months, and includes 
SPPB and hand grip strength, anthropometric measure-
ments, a five level version of the EuroQol five dimension 
(EQ-5D-5L) questionnaire, a short Food Frequency Ques-
tionnaire (FFQ), and a 24-hour food-recall interview. The 
researcher will complete the questionnaires based on a 
structured interview with each participant. Furthermore, 
the participants will be instructed to visit their general 
practitioner for blood sampling. The researcher will 
perform all other assessments.
Main outcome: sPPb
Muscle performance will be measured with the SPPB, 
a test battery developed originally for the Established 
Populations for Epidemiologic Studies of the Elderly and 
translated into Norwegian in 2013 by Bergh et al.25 The 
test battery includes standing balance, walking speed and 
repeated chair rise. Each of the three domain scores range 
from 0 to 4 points, yielding an integer score ranging from 
0 to 12 points. A higher score indicates a higher level of 
functioning, and a change of one unit is considered a clin-
ically meaningful change.26 A systematic review of instru-
ments assessing performance-based physical function in 
older community-dwelling persons concluded that the 
SPPB can be highly recommended in terms of validity, 
reliability and responsiveness.27 The SPPB complements 
self-reported disability and may predict mortality and 
nursing home admission even at the high end of the func-
tional spectrum.28 Gait speed may be calculated as metres 
per second from the 4 m walking test included in SPPB. 
Gait speed alone is nearly as useful as the full battery for 
predicting disability. However, the assessment of balance 
and chair-rise ability is clinically important.29
secondary outcome: hand grip strength
Hand grip strength is measured to the nearest 0.1 kg using 
the Jamar Plus +digital hand dynamometer. We will record 
three trials from each hand, with participants in a sitting 
position and the arm at a 90° angle, as described in Roberts 
et al.30 The maximum of these values will be used for anal-
yses.31 Grip strength is a useful and simple measure of muscle 
strength. It correlates with leg strength, is a clinical marker of 
poor mobility and is considered a better predictor of clinical 
outcomes than low muscle mass.2 Cut-off scores are set to 
30 kg and 20 kg for men and women, respectively.2 However, 
Dodds et al provide normative data with centile values for 
grip strength across the life course.31
secondary outcome: health-related quality of life
Health-related quality of life (HRQOL) will be assessed by 
the EQ-5D-5L questionnaire.32 The EQ-5D-5L consists of 
the EQ-5D descriptive system and the EQ Visual Analogue 
Scale (EQ VAS). The descriptive system comprises the 
following five dimensions: mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression. Each 
dimension has five levels: no problems, slight problems, 
moderate problems, severe problems and extreme prob-
lems. The VAS assesses subjective health on a 0–100 scale, 
with 0 representing the worst possible and 100 the best 
possible health. EQ-5D-5L has been validated in a diverse 
population in several countries, including multiple 
patient groups with chronic conditions.33
Explanatory variables
The age, gender, physical activity and educational level of 
the participants may influence both nutritional status and 
physical function and are regarded as explanatory factors. 
Moreover, we believe that living alone or with a partner may 
influence dietary intake, as social relations affect food habits. 
Weight, body mass index (BMI) and muscle mass are also 
regarded as explanatory factors. Body mass is recorded in 
light clothing to the nearest 0.1 kg using a digital scale (Seca 
803) and height and leg circumference with a tape measure 
(Seca 201). Muscle mass will be estimated from calf circum-
ference and weight, using equation 1.34
 
 
MM(kg) = −0.543 + (0.162 ∗ body mass)+
(0.151 ∗ calf circumference)  
 (1)
nutritional status
An assessment of nutritional status will be made by 
the nutritional screening and assessment tool, Mini 
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Nutritional Assessment (MNA), and biomarkers in 
serum/blood. The MNA tool was developed by Nestlé 
Nutrition Institute and is commonly used worldwide.35 
The full version comprises 18 items contributing to a 
sum score of 0–30 points. The reliability and validity of 
the full MNA is well established across care settings and 
has a sensitivity of 96% and specificity of 98% compared 
with clinical status. The specificity is lower compared 
with other nutritional assessment methods; however, 
sensitivity remains strong.35 The MNA is recommended 
by the Norwegian Directorate of Health to assess nutri-
tional status in elderly persons.36
Non-fasting blood samples will be collected for the 
determination of albumin, prealbumin, retinol-binding 
protein, glycated haemoglobin A1c and vitamin D 
(25-hydroxy vitamin D) as well as markers of inflamma-
tion,that is, C reactive protein and creatine kinase. The 
blood samples will be analysed in hospital laboratories 
(standard routine analyses). Visceral proteins (albumin, 
prealbumin and retinol-binding protein) are commonly 
used as biomarkers of nutritional protein status and 
regarded as useful indices in the assessment of malnu-
trition among the elderly.37 Vitamin D is important for 
maintaining bone health, and its deficiency may predict 
hip fracture.38 A supplement of whey protein enriched 
with vitamin D improved muscle mass in sarcopenic 
older adults.16 Hence, the analyses in this project should 
control for vitamin D status.
nutritional intake
Daily energy (kcal/day) and protein intake (g/day) will be 
estimated using a 24-hour recall of food intake, following 
the protocol and method described in the Newcastle 
85+study (freely available at the website for the Medical 
Research Council in the UK).39 To adapt the method to 
Norwegian participants, we use the food-portion illus-
trated booklet (with a corresponding list of weights) from 
the Norwegian study ‘Ungkost 2000’.40
The multiple-pass recall (MPR) method can accurately 
assess intakes regardless of the subjects’BMI.41 42 As this 
study recruits participants without an upper age limit, a 
dietary assessment method also applicable for the very 
old was chosen. The 24-hour food recall was considered 
the preferred method for dietary assessment among 
the oldest old (85+years), based on both performance 
and practical applicability in this age group.43 The esti-
mated daily energy, protein and other nutrients intakes 
are better aligned with the corresponding means from 
weighed dietary intakes in the UK National Diet and 
Nutrition Survey, compared with the FFQ.43
Both MPR and FFQ measured higher intakes than the 
weighed intake in the 85+study. This might be due to an 
overestimation of intake in the two retrospective methods, 
but as prospective methods tend to affect food intake,44 
the retrospective methods still might be more represen-
tative of true intake. Seafood intake will be assessed by a 
validated FFQ.45
Views on nutrition and need for nutritional support
A questionnaire developed for this study, asks partici-
pants to agree or disagree with statements about food and 
nutrition, for example, ‘I prefer to eat alone’ or ‘Food 
doesn’t taste like it used to’. Moreover, we ask the partic-
ipants whether they receive help preparing and eating 
their meals, and who they prefer to consult for nutritional 
advice. These data will be presented descriptively in rela-
tion to nutritional status and intake.
Intervention
The participants will take the supplement in tablet form 
and will be instructed to take five tablets two times a day, 
preferably in relation to breakfast and the evening meal. 
Each tablet contains 300 mg of MPH (Nx6.25), which 
yields a total dose of 3 g per day (1.5 g morning and 
1.5 g evening) in accordance with other studies,21 24 The 
tablets are produced by Flexipharma AS and based on 
the marine peptide compound 565952 P from Firmenich 
Bjørge Biomarin AS. Placebo tablets are produced based 
on gum arabic. The marine peptide compound is manu-
factured through the hydrolysis of fresh or fresh-frozen 
Atlantic Cod fillet (Gadus morhua) using industrial food 
approved non-GMO proteolytic enzymes and added 
maltodextrin from corn to prevent the odour and taste of 
fish. Hydrolysis is conducted using equipment and proce-
dures according to regulations provided by the Norwe-
gian food authorities. Marine peptides are approved as a 
food ingredient in Norway according to EU regulations.
Compliance
Compliance will be assessed by calculating the percentage 
of supplement taken. The participants will be asked to 
keep a record of their supplement intake, and questions 
on compliance will be asked at the 6 and 12 months 
follow-ups.
randomisation and blinding
The participants will be given project identification 
numbers, which will be randomised into two groups. 
Block randomisation will be performed, with blocks 
based on the baseline score of the SPPB test. The main 
researcher (LAKN) enrols participants and forwards 
identification numbers and block information to the stat-
istician (JŠB), who performs the randomisation to either 
group A or group B. The group A or B allocation will be 
sent to a person not connected to the project, who will 
prepare supplement and placebo boxes by marking them 
with an identification number only. Trial participants, 
care providers, outcome assessor and data analysts are 
blinded for the intervention, and the intervention groups 
will not be revealed until all data have been analysed.
sample size and statistical power calculation
The main outcome of this study is physical performance, 
as measured by the SPPB on a 12-point scale. In accor-
dance with previous studies, a clinically meaningful 
change in score on this scale is reported to be 0.4–1.5 
points.26 Based on this study, we assume that the mean 
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SPPB score at inclusion is 7.52 in both groups. We also 
assume that the intervention group maintains a stable 
SPPB score throughout the study period, while the score 
decreases by an average 0.9 points in the control group. 
In addition, we assume that the SD after the intervention 
period is 1.42 in both groups. A sample size of 41 partic-
ipants is required in each group to detect a statistically 
significant mean difference of 0.9 points at a significance 
level of 5% and with a power of 80% using a two-sided 
independent samples t-test. As the participants are older, 
we expect a drop-out/missing frequency of 20%; there-
fore, we aim to include 50 participants in each group.
statistical analyses
The demographic and clinical characteristics of the partic-
ipants in each group will be described as means and SDs 
or frequencies and percentages, as appropriate. A linear 
mixed model will be estimated to assess the effect of MPH 
on the primary outcome, the SPPB, in the intervention 
and placebo groups throughout the 12-month follow-up. 
The model will include fixed effects for time components 
up to the second order, group allocation and the inter-
action between the two. Random effects for participants 
will be included to correctly adjust estimates for possible 
intraparticipant correlations due to repeated measure-
ments for each participant. Random slopes for time 
component will be considered. A significant interaction 
between time and group allocation would imply differ-
ences in SPPB scores between the groups throughout 
the follow-up. Pairwise comparisons will be conducted 
by deriving individual time point contrasts within each 
group with corresponding 95% CIs and p values. The 
results will be further adjusted for a number of covariates 
(age, gender, education, physical activity, living status, 
seafood intake, nutritional status, vitamin D level and 
energy intake). Secondary outcomes, hand grip strength 
(kg), HRQOL measured by the EQ-5D-5L and health as 
measured by the VAS will be assessed by similar models. 
The results will be tabulated and presented graphically to 
facilitate their interpretation.
To assess whether nutrition is associated with SPPB, 
HRQOL and hand grip strength at baseline, linear mixed 
models will be estimated. Nutrition will be the main fixed 
effect in all models. The models will be further adjusted 
for a number of other important variables including 
age, gender, living status, seafood intake, vitamin D 
level, protein nutrition markers, habitual protein intake, 
protein intake and energy intake.
As participants will be recruited from different munic-
ipalities, within-municipality correlations might be 
present in the data. To correctly adjust for such correla-
tions, random effects for municipality will be included 
in all models. The multiple models will be reduced by 
applying Akaike’s information criterion. Model assump-
tions will be assessed as appropriate and, in the event 
of violations, necessary adjustments implemented. The 
statistical analyses will be performed using SPSS V.24 
and SAS V.9.4. Results with p values below 0.05 will be 
considered statistically significant. The intention-to-treat 
sample will be used in statistical analysis, and per-protocol 
analysis will be performed if relevant.
Preregistration
The trial is preregistered at http://www. clinicaltrials. gov.
dIsCussIon
The main purpose of this study is to examine the effects 
of MPH on physical performance in a population of older 
people. The double-blinded randomised controlled 
design is considered solid and sound for answering 
the main research question. Furthermore, this project 
provides important data on nutritional status and intake 
in this population. To gain a deeper understanding of 
the results of the randomised controlled trial, additional 
questions are included to provide a descriptive analysis 
on nutrition and factors influencing the nutritional status 
of older people.
The population of interest is older people. The partic-
ipants are recruited either by invitation from the home 
care service or recruited from advertisements in local 
media, senior centres and suchlike. People with moderate 
or severe cognitive impairment, which can be considered 
to interfere with their capacity to give written informed 
consent, will not be approached to participate in the study, 
and this represents a limitation. However, we consider the 
recruitment procedure to provide a selection of partic-
ipants who are potentially representative of the prefrail 
segment of the elderly population and thereby the target 
population for the intervention. Frailty partially overlaps 
the generally accepted concept of being ‘old and weak’, 
but it is not synonymous with comorbidity or disability; 
comorbidity is rather a risk factor for frailty, and disability 
can be an outcome of frailty.46 Fried provided a definition 
of frailty as a clinical syndrome in which three or more of 
the following criteria are present: unintentional weight 
loss, self-reported exhaustion, weakness (grip strength), 
slow walking speed and low physical activity.46 Later, these 
key indicators of frailty were discussed, and concerns 
were raised about the value of self-reported exhaustion 
and muscle weakness. However, slow gait speed, low 
physical activity, weight loss and cognitive impairment 
are still regarded as strong indicators of frailty.47 All of 
these factors may also reflect poor nutritional status, and 
additional studies on associations between nutrition and 
frailty are needed to address the challenges of frailty in 
old age. This study will focus on the sarcopenia-related 
indicators of frailty in elderly persons and the possibility 
of preventing sarcopenia and frailty through nutritional 
intervention.
A strength of this study is its comprehensive data collec-
tion. To the best of our knowledge, no previous study 
of physical performance in the elderly includes a thor-
ough assessment of the participants’ nutritional intake 
and status as this study does. Documentation regarding 
nutrition in home-dwelling elderly persons is sparse, 
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although a prevalence study of 340 home-dwelling older 
persons receiving home care services in Oslo, Norway, 
reported that 46% were categorised as being or at risk of 
being, malnourished.48 Malnutrition among the elderly 
population is a serious concern, and at the University of 
Oslo, the cost-effectiveness of preventing malnutrition 
compared with treating it has been estimated at a savings 
of Kr800 million (ca. €86 million).49 In the case of insuffi-
cient intake of calories (negative energy balance), dietary 
proteins are used for energy utilisation rather than 
muscle protein synthesis.5 50 General malnutrition may, 
therefore, hasten the development of sarcopenia despite 
protein supplements. Thus, it is necessary to control for 
both general nutrition and protein nutrition status when 
assessing the effects of protein supplements on the devel-
opment of sarcopenia.
Interventions designed to counteract age-related 
sarcopenia and help older people to maintain physical 
functioning are needed to meet the challenges of the 
increasing life span. As the average life span in Norway 
now exceeds 80 years, we aim to delay the need for 
help and care, from a socioeconomic perspective and 
to increase the quality of the additional years of life. We 
know that exercise and nutrition are important factors in 
preventing muscle loss.8 However, when we are the most 
vulnerable for muscle loss, for example, during bed rest 
after injury or illness, both appetite and the ability to 
exercise are reduced. Thus, the use of food supplemen-
tation to maintain muscle health in these situations will 
highly benefit an ageing population.
Dietary protein intake should be distributed over 
several meals, as there seems to be a protein threshold 
for the onset of MPS between 20 g and 40 g of protein per 
meal.8 12 15 MPH or fish protein could stimulate MPS at 
lower doses of 1.4–6.0 g.21 24 As muscle atrophy appears to 
happen rapidly after disuse/bed rest,18 stimulating MPS 
is of importance in situations of low activity and poor 
protein nutrition. A strength of this study is that the MPH 
supplement is to be taken in relation to breakfast and 
the evening meal, not dinner. This will provide a more 
evenly distributed protein intake/stimulation of MPS. To 
the best of our knowledge, there are no previous studies 
of distribution of protein intake in Norway. However, the 
lunchtime meal will typically contain less protein than in 
countries like the USA, and we believe that protein intake 
is less distributed than reported in the National Health 
and Nutrition Examination Survey (NHANES) study in 
the USA.12
A limitation of our study may be the anthropometric 
method used to assess muscle mass. According to the 
European Working Group on Sarcopenia in Older People 
(EWGSOP) consensus on the definition of sarcopenia, 
both muscle mass and muscle function (strength and 
performance) need to be assessed to identify sarcopenia.2 
The EWGSOP recommends anthropometric measure-
ments of muscle mass for clinical use only, as there are 
few studies validating anthropometric measurements in 
the elderly population, and they are vulnerable to errors. 
However, in the present study, we use an inexpensive 
measurement that is easy to perform in the participants’ 
homes. Hence, muscle mass is estimated from calf circum-
ference and weight, with the equation for the estima-
tion of muscle mass described by Santana.34 In multiple 
regression analysis of anthropometric measures in elderly 
women, body mass and calf circumference estimated 
muscle mass (measured by Dual-energy X-ray absorpti-
ometry (DXA)) adequately (r 0.81), but it has not been 
validated and is tested only in women. Anthropometric 
estimation of muscle mass is considered vulnerable to 
error.2 However, some studies argue for the use of calf 
circumference alone as a marker of sarcopenia in older 
adults.51 We have chosen physical function (SPPB) as our 
primary outcome, as there is growing evidence that loss of 
strength is a more consistent risk for disability and death 
than is loss of muscle mass.52
The project will have potential benefits for the target 
population. Increased knowledge of nutritional status and 
protein intake among this population group may facili-
tate nutritional interventions to prevent loss of physical 
function, potentially leading to increased independence 
and delayed need for residential institution. The results 
of this study may also be transferable to other populations 
with conditions where muscle atrophy is a concern, for 
example, inactivity after injuries, bed rest after surgery or 
in intensive care units.
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